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Abstract 
Background: Patients with type II diabetes are at major risk for cardiovascular disease. Sodium-glucose 
cotransporter-2 inhibitors (SGLT-2 inhibitors) have demonstrated benefit for these patients. The purpose 
of this study is to determine whether SGLT-2 inhibitors significantly reduce heart failure readmission rates 
and improve outcomes in patients with congestive heart failure (CHF). 
Methods: Patient data was pulled on CHF patients with an active prescription for an SGLT-2 inhibitor, and 
it was analyzed using Fischer’s Exact tests and two-tailed t-tests. The primary outcome was a 6-month 
hospital readmission rate due to CHF while taking SGLT-2 inhibitors. Secondary outcomes included 
6-month all-cause hospital readmissions, renal function as measured by an estimated glomerular 
filtration rate change between admissions, mortality rates, and ejection fraction. 
Results: Of the 138 patients that met inclusion criteria for the first admission, the 6-month all-cause 
readmission rate for CHF patients still taking SGLT-2 inhibitors at readmission was 21 percent vs 16 
percent (p=0.6) for the control group not taking SGLT-2 inhibitors. The 6-month CHF readmission rate in 
patients taking SGLT-2 inhibitors was 7.2 percent, and a CHF specific readmission rate was not collected 
for the control group. In patients with an eGFR less than 90, the average eGFR for the SGLT-2 group 
declined slightly but was not significant between patients at first admission and those with readmission 
(p=0.21). 
Conclusion: The use of SGLT-2 inhibitors in patients with CHF did not change the overall hospital 
readmission rate; however, larger randomized controlled trials are needed for further evaluation of the 
potential benefit. 
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INTRODUCTION
Cardiovascular disease is the number one leading cause of death for 
Americans.1 Congestive Heart Failure (CHF) is a prominent heart disease 
marked by progressive structural changes in the heart, resulting in 
inefficient filling and emptying of its chambers. An abnormality in 
systolic function and/or diastolic function might be the cause of CHF. 
Heart failure with reduced ejection fraction (HFrEF) results from a 
reduced systolic function whereas heart failure with preserved ejection 
fraction (HFpEF) is indicative of a preserved (normal) left ventricular 
function.2 Many factors including age, gender, renal function, diabetes, 
and medications can affect the prognosis of patients with CHF.3
Type II diabetes is a major contributing factor to the development of 
heart disease as it is present as a comorbid condition in 25% to 40% of 
patients with CHF.2,4 This noninsulin-dependent diabetes is caused by 
β-cell dysfunction coupled with insulin resistance and defective insulin 
secretion related to genetics and lifestyle factors.5 Commonly diagnosed 
comorbid conditions for patients with type II diabetes are hypertension 
and dyslipidemia. Therefore, diabetes does not only increase the risk of 
CHF, but it also plays a significant role as predictor of morbidity and 
mortality in patients with a previously established diagnosis of CHF.4,6 
Data demonstrates that the link between diabetes and CHF may be more 
pronounced than previously believed.7 The prevalence of heart failure 
and type II diabetes is expected to continue rising in the United States 
(US). Currently, 29 million adults in the US have type II diabetes and 
6.5 million suffer from heart failure.8 The pathophysiology of diabetes 
in HFpEF is demonstrated by an increased microvascular endothelial 
inflammation accompanied with hyperinsulinemia resulting in cardio-
myocyte stiffness and hypertrophy. Therefore, left ventricular diastolic 
dysfunction worsens as a result of larger and stiffer cardiomyocytes. On 
the other hand, cardiomyocyte death is more commonly seen in diabetic 
patients with HFrEF.4 Since the pathophysiology of CHF and type II 
diabetes seem to be strongly linked, drugs that improve diabetes may 
also have efficacy for the treatment of CHF.
One option for treating type II diabetes is using a sodium-glucose 
co-transporter-2 (SGLT-2) inhibitor, which treats this adult-onset diabetes 
by inhibiting the reabsorption of glucose by the kidneys, thus preventing 
high blood sugar levels. There is some evidence that these SGLT-2 
medications may offer cardiovascular benefits. The 2021 American 
Diabetes Association (ADA) guidelines state that SGLT-2 inhibitors 
significantly reduce cardiovascular events, recommending their addition 
in patients with type II diabetes and atherosclerotic cardiovascular 
disease (ASCVD) with uncontrolled blood sugar while using metformin 
or lifestyle modifications.9 
SGLT-2 inhibitors are currently recognized by the ADA to reduce 
cardiovascular events but are not included in heart failure guidelines as 
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first-line agents. However, in the 2021 Update to the 2017 ACC Expert 
Consensus Decision Pathway, SGLT-2 inhibitors are now recommended 
as first-line therapy for all patients.10
At the time of this study, canagliflozin and empagliflozin were the only 
SGLT-2 inhibitors United States Food and Drug Administration (FDA) 
indicated for the prevention of cardiovascular outcomes in patients with 
existing diabetes. Dapagliflozin has since been approved following the 
DAPA-HF trial. These three SGLT-2 inhibitors have been shown to offer 
improved outcomes in patients with HFrEF receiving guideline-directed 
medical therapy.11,12
Empagliflozin was featured in EMPA-REG OUTCOME with a diverse 
patient population, of whom 65% had a medical history of myocardial 
infarction or stroke and all patients had greater than 12% risk for 
cardiovascular events in 10 years. Patients on empagliflozin demonstrated 
reductions in all-cause mortality, cardiovascular death, nonfatal infarcts, 
and nonfatal strokes. The authors concluded that empagliflozin was able 
to demonstrate consistent reduction in mortality and cardiovascular 
events despite studying a patient population with a broad range of 
cardiovascular histories and ASCVD risk.13
Among patients in the DAPA-HF trial with heart failure and a reduced 
ejection fraction, the risk of worsening heart failure or death from 
cardiovascular causes was lower among those who received dapagliflozin 
than those who received placebo, regardless of the presence or absence 
of diabetes. Dapagliflozin is the first SGLT-2 inhibitor to be approved for 
patients independent of diabetes status.14
Like the authors of the DAPA-HF trial, we sought to gather data related to 
the impact of SGLT-2 inhibitors. Our patient population had established 
heart failure independent of diabetes status. Our study aimed to evaluate 
the efficacy of SGLT-2 inhibitors in decreasing hospital admission rates 
and improving the overall condition of heart failure. We also looked at 
the usage of first-line CHF medications in our study to determine if 
patients were on appropriate first-line therapy. For the established 
treatment of CHF, first-line therapies include angiotensin-converting 
enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), be-
ta-blockers, and diuretics as needed for fluid retention.14 The aim of the 
present study is to investigate what benefit, if any, SGLT-2 inhibitors 
provide to heart failure patients with or without diabetes for the possibility 
of these medications becoming standard of care.
MATERIALS AND METHODS
The Institutional Review Board (IRB) of Sanford Health approved 
our one-center retrospective cohort study on February 6th, 2020. 
HIPAA authorization was waived for this approved IRB protocol #: 
STUDY00001918, to evaluate the efficacy of SGLT-2 inhibitors in reducing 
heart failure readmission rates. Patient data from 2013 to 2019 was 
collected and analyzed for 6 months past the first admission. The sanford 
Information Technology Department pulled patient information for 
study inclusion criteria. Data collection took place at Sanford USD 
Medical Center in Sioux Falls, South Dakota, from February to March 
2020. Information was de-identified and analyzed from March to April 
2020. Statistical analysis was done using Fischer exact tests and 
two-tailed T-tests.
The primary outcome was 6-month hospital readmission rates due to 
heart failure while taking SGLT-2 inhibitors. Secondary outcomes 
included 6-month all-cause hospital readmissions, renal function as 
measured by eGFR change between admissions, mortality rates, and 
presence of HFrEF versus HFpEF while taking SGLT-2 inhibitors.
Inclusion Criteria
• Patients 18 years or older with a diagnosis of CHF (as designated 
by the International Classification of Diseases (ICD) 9/10 codes),
• Patients require an active prescription for an SGLT-2 inhibitor, 
• Patients must have a creatinine clearance (CrCl) greater than 
30 mL/min. 
Exclusion Criteria
• Patients with heart failure class IV, end-stage renal disease (ESRD), 
and dialysis.
• Patients who discontinued their SGLT-2 inhibitor before the second 
admission.
At baseline, most patients were taking at least one first-line medication 
for heart failure, suggesting proper management. For the first admission 
for CHF, 138 patients met inclusion criteria. Of those, 72 patients were 
taking either an ACE Inhibitor or an ARB, 88 were taking beta-blockers, 
71 were taking diuretics, and 18 patients were not receiving any first-line 
medication for CHF before hospitalization.  Of those taking medications, 
29 patients were taking one agent, 58 patients were taking two agents, 
and 34 patients were taking more than two agents, as shown in Figure 1. 
As a part of the inclusion criteria, all patients were taking an SGLT-2 
inhibitor as shown in Figure 2. Most patients were taking canagliflozin 
(51), while others were taking empagliflozin (40), dapagliflozin (21), or 
a combination medication such as canagliflozin-metformin (7), 
empagliflozin-linagliptin (6), or empagliflozin-metformin (2). Due to 
the impact of the COVID-19 pandemic on data collection, no further 
patient demographics were collected. 
We were able to pull a matched cohort group to our data set so we could 
compare readmission rates. A total of 78,000 patients with CHF from 
2013 to 2019 who were not taking SGLT-2 inhibitors were included 
in this data set. Due to time constraints of data collection and the 
COVID-19 pandemic, we were unable to gather any additional informa-
tion about this patient population other than readmission rates.
RESULTS
In patients taking SGLT-2 inhibitors, the 6-month all-cause readmission 
rate was 21%, compared to a readmission rate of 16% in those patients 
not taking SGLT-2 inhibitors.
Additionally, 10 of 138 patients (7.2%) taking a SGLT-2 inhibitor were 
readmitted for a specific diagnosis of CHF as depicted in Figure 3. 
A readmission rate for a specific diagnosis of CHF was not collected 
for the control group not taking SGLT-2 inhibitors. A Fisher Exact test 
comparing all-cause readmission rate of those taking SGLT-2 inhibitors 
to the control group produced a P-value of 0.6, which was not signifi-
cantly different.
Figure 1: Baseline heart failure medication use.
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(62%) as shown in Figures 5 and 6. These changes were not significant 
(p=0.81). Patients who did not have a recent echocardiogram within one 
month of admission were excluded.
During the first admission, 1 out of 131 patients did not have a diagnosis 
of type II diabetes. During the second admission, all 29 patients had a 
diagnosis of type II diabetes.
The study also evaluated mortality rate of those taking SGLT-2 inhibitors 
and who also were diagnosed with CHF. Patients who died after 6 months 
of their first admission were included in this mortality rate. At data 
collection, 20.3% of patients with a first admission had died. Unfortu-
nately, similar to other endpoints, mortality rate could not be compared 
to a control group due to COVID restrictions.
DISCUSSION
The 6-month all-cause readmission rate for patients taking SGLT2-
inhibitors was not significantly different than the readmission rate for 
those not taking SGLT-2 inhibitors (21% vs 16%).  These 6-month 
readmission rates were lower than the reported statistic from the 2013 
American College of Cardiology (ACC)/American Heart Association 
(AHA) Heart Failure Guidelines, where patients hospitalized for CHF 
had a 1-month readmission rate of 25% for all-cause rehospitalization.15,16
The mortality rate of 20.3% in this study was similar to that reported 
in the 2013 American College of Cardiology Foundation (ACCF)/AHA 
Heart Failure Guidelines. According to the 2013 ACCF/AHA Heart 
Failure Guidelines, the absolute mortality rates for CHF remain 
approximately 50% within 5 years of diagnosis. In the ARIC study, the 
Figure 2: SGLT-2 inhibitor breakdown.
Figure 3: Readmission rates on SGLT-2 inhibitors.
Figure 4: eGFR change between admissions. (p=0.21).
Figure 5: Prevalence of HFrEF vs. HFpEF first admission.
Figure 6: Prevalence of HFrEF vs. HFpEF at readmission.
In patients with an eGFR less than 90, the average eGFR for the SGLT-2 
group declined slightly but non-significantly from 57.9 mL/min/1.73m2 
to 52.8 mL/min/1.73m2 between patients at first admission and those 
with readmission (p=0.21) as shown in Figure 4. 
The prevalence of HFpEF and HFrEF was comparable between first 
admission and those with readmission, with 35 of 105 first time admits 
(33%) and 8 of 21 second time admits (38%) reporting HFrEF with an 
ejection fraction <40%. The rest of the patients with data were HFpEF, 
with 70 of 105 first time admits (67%) and 13 of 21 second time admits 
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ABBREVIATIONS
ACC: American College of Cardiology; ACCF: American College of 
Cardiology Foundation; ADA: American Diabetes Association; AHA: 
American Heart Association; ASCVD: Atherosclerotic cardiovascular 
disease; CHF: Congestive heart failure; CrCl: Creatinine clearance; 
eGFR: Estimated glomerular filtration rate; ESRD: End-stage kidney 
disease; FDA: United States Food and Drug Administration; HF: Heart 
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cation of Diseases; SGLT-2 inhibitors: Sodium-glucose cotransporter-2 
inhibitors.
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30-day, 1-year, and 5-year case fatality rates after hospitalization for CHF 
were 10.4%, 22%, and 42.3%, respectively.17
We found no significant differences with HFrEF or eGFR, so our data 
cannot be used to support efficacy for renal or heart failure outcomes.
This study has some limitations. Since our data was collected using 
diagnostic codes, a patient might have been coded for CHF even if it was 
not the main cause of the admission. Therefore, to find the CHF specific 
readmission, we did a manual chart review to find where CHF was listed 
as a cause of the admission according to provider documentation, which 
may be subject to error. 
Another major limitation of this study was small sample size. The 
primary outcome statistical result could be due to a type II error where 
we failed to find a difference although one may have existed if we had a 
larger sample size. Due to the small number of patients in the readmission 
group, we were unable to perform some of the exploratory analyses 
that we planned. We did not perform subgroup analysis by individual 
SGLT-2 inhibitor, or look at a subset analysis of patients without diabetes 
that were taking a SGLT-2 inhibitor.
This study also had several strengths. A strength of this study is that 
most patients received appropriate first-line therapy for CHF (120 of 138 
patients), so we can be sure that patients were receiving some treatment 
for CHF. However, the effect of the other therapies for CHF on these 
results was not studied. Another strength was that patients were well 
distributed between SGLT-2 inhibitors, so we were able to look at the 
class benefit of SGLT-2 inhibitors.
It was also positive that there was not a significant decrease in average 
eGFR between readmissions. This could be interpreted as SGLT-2 
inhibitors preventing a decline in renal function and a topic for future 
clinical research. It should be noted that those patients with eGFR 
>90 mL/min/1.73m2 (normal renal function) were not included in the 
statistical analysis to prevent skewing the data. Other strengths of this 
study include a large health system to pull data, a matched cohort control 
group to compare readmission rates, and limited exclusion criteria.
For future direction, it would also have been beneficial to extend data 
collection for readmissions longer than 6 months to increase sample size. 
Finally, it is important to note that CHF is most often accompanied with 
a multitude of other disorders and comorbidities that can affect patients’ 
treatment approach, morbidity, and mortality differently.
CONCLUSION
The use of SGLT-2 inhibitors in patients with CHF did not significantly 
change the overall hospital readmission rate; however, this study reports 
better readmission values than those reported in the literature. Larger 
randomized controlled trials are needed for further evidence of this 
indication. More data could help incorporate SGLT-2 inhibitors into 
standard care for heart failure. Now that dapagliflozin is approved as an 
adjunct heart failure agent, we hope that this study aids clinicians in the 
use of SGLT-2 inhibitors. Safety and cost are variables that would need 
to be addressed. Head-to-head trials of SGLT-2 inhibitors would help 
prescribers choose the best agent.
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